Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation
De Leval, X.; Benoit, V.; Delarge, J.et al.
2003 • In Prostaglandins, Leukotrienes, and Essential Fatty Acids, p. 55-59
Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation
Publication date :
2003
Journal title :
Prostaglandins, Leukotrienes, and Essential Fatty Acids
ISSN :
0952-3278
Publisher :
Churchill Livingstone, Inc., Edinburgh, United Kingdom
S. Karpatkin, E. Pearlstein, Role of platelets in tumor cell metastases, Ann. Intern. Med. 95 (1981) 636-641.
G.J. Gasic, T.B. Gasic, N. Galanti, T. Johnson, S. Murphy, Platelet-tumor-cell interactions in mice, The role of platelets in the spread of malignant disease, Int. J. Cancer 11 (1973) 704-718.
K.V. Honn, D.G. Tang, Y.Q. Chen, Platelets and cancer metastasis: more than an epiphenomenon, Semin. Thromb. Hemost. 18 (1992) 392-415.
G.J. Gasic, T.B. Gasic, Removal of sialic acid from the cell coat in tumor cells and vascular endothelium and its effects on metastasis, Proc. Natl. Acad. Sci. USA 48 (1962) 1172-1177.
G.J. Gasic, T.B. Gasic, C.C. Stewart, Antimetastatic effects associated with platelet reduction, Proc. Natl. Acad. Sci. USA 61 (1968) 46-52.
E. Pearlstein, C. Ambrogio, G. Gasic, S. Karpatkin, Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic routine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide, Prog. Clin. Biol. Res. 89 (1982) 479-502.
A. Tohgo, N.G. Tanaka, H, Ogawa, Platelet-aggregating activities of metastasizing tumor cells. III. Platelet aggregation as resulting from thrombin generation by tumor cells, Invasion Metastasis 5 (1985) 96-105.
K.E. Ugen, M. Mahalingam, P.A, Klein, K.J. Kao, Inhibition of tumor cell-induced platelet aggregation and experimental tumor metastasis by the synthetic Gly-Arg-Gly-Asp-Ser peptide, J. Natl. Cancer Inst. 80 (1988) 1461-1466.
E. Bastida, A. Ordinas, S.L. Giardina, G.A. Jamieson, Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase, Cancer Res. 42 (1982) 4348-4352.
Y. Katagiri, Y. Hayashi, I. Baba, H. Suzuki, K. Tanoue, H. Yamazaki, Characterization of platelet aggregation induced by the human melanoma cell line HMV-I: roles of heparin, plasma adhesive proteins, and tumor cell membrane proteins, Cancer Res. 51 (1991) 1286-1293.
E. Pearlstein, P.L. Salk, G. Yogeeswaran, S. Karpatkin, Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line, Proc. Natl. Acad. Sci. USA 77 (1980) 4336-4339.
J.M. Dogné, X. de Leval, J. Delarge, J.L. David, B. Masereel, New trends in thromboxane and prostacyclin modulators, Curr. Med. Chem. 7 (2000) 609-628.
K.V. Honn, Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system, Clin. Exp. Metastasis 1 (1983) 103-114.
M.L. Ogletree, Overview of physiological and pathophysiological effects of thromboxane A2, Fed. Proc. 46 (1987) 133-138.
D. Nie, M. Lamberti, A. Zacharek, L. Li, K. Szekeres, K. Tang, Y. Chen, K.V. Honn, Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis, Biochem. Biophys. Res. Commun. 267 (2000) 245-251.
I. Yokoyama, S. Hayashi, T. Kobayashi, M. Negita, M. Yasutomi, K. Uchida, H. Takagi, Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor, Res. Exp. Med. 195 (1995) 209-215.
P. Mehta, D. Lawson, M.B. Ward, L. Lee-Ambrose, A. Kimura, Effects of thromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation, Cancer Res. 46 (1986) 5061-5063.
C. Voland, C.M. Serre, P. Delmas, P. Clezardin, Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1, J. Bone Miner. Res. 15 (2000) 361-368.
P. Clezardin, J. Drouin, M.C. Morel-Kopp, M. Hanss, B. Kehrel, C.M. Serre, C. Kaplan, P.D. Delmas, Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells, Cancer Res. 53 (1993) 4695-4700.
K.V. Honn, D.G. Menter, J.M. Onoda, J.D. Taylor, B.F. Sloane, Role of prostacyclin as a natural deterrent to hematogenous tumor metastasis, Symp. Fundam. Cancer Res. 36 (1983) 361-388.
B. Nieswandt, M. Hafner, B. Echtenacher, D.N. Mannel, Lysis of tumor cells by natural killer cells in mice is impeded by platelets, Cancer Res. 59 (1999) 1295-1300.
A. Tohgo, N.G. Tanaka, Y. Osada, Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium, Invasion Metastasis 10 (1990) 1-17.
